The vascular endothelial growth factor (VEGF) family of soluble protein growth factors
consists of key mediators of angiogenesis and lymphangiogenesis in the context of tumor …

Background: Angiogenesis is essential for cancer growth and metastasis. VEGF is a key
modulator of angiogenesis and its overexpression is correlated with advanced disease and …

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and
an angiogenic inducer in vivo. The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR …

VEGFs and a respective family of tyrosine kinases receptors (VEGFRs) are key proteins
modulating angiogenesis, the formation of new vasculature from an existing vascular …

Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis
and is an important target in the development of anticancer drugs. However, VEGF receptor …

Abstract Purpose: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis
agents, have been applied in the cancer treatment. However, currently most of these …

Angiogenesis, the growth of new blood vessels is essential during fetal development, female
reproductive cycle, and tissue repair. In contrast, uncontrolled angiogenesis promotes the …

The vascular endothelial growth factor (VEGF) signaling pathway appears to be the
dominant pathway involved in tumor angiogenesis, providing a rationale for targeting the …

Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

Abstract Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular
endothelial growth factor, was approved by the US FDA in February 2004 for the first-line …